Colorectal cancer is the second leading cause of cancer in Canadians with liver metastases being the major cause of death from this disease. Dr. Metrakos and his colleagues are using blood test analysis (Liquid Biopsy) to 1) identify colorectal cancer liver metastases (CRCLM) patients who will have targetable mutations, and 2) monitor the development of recurrence and drug resistance (non-responders). It is expected that this knowledge will lead to optimization of current treatment strategies, including integration of a dedicated molecular tumor board, a precision therapy approach to the management of metastatic disease and cost savings for the health care system.
Genome Centre: Génome Québec
Users:
| Loubna | Jouan | Roche Diagnostics, division of Hoffmann-La Roche Ltd. |
| Julie | Quenneville | Fondation du CUSM |